Abstract
Myasthenia gravis is an acquired autoimmune disease, which influences the postsynaptic membrane and makes affected muscle pathological fatigue.In recent years, many research results show that a variety of immune inhibitors and monoclonal antibody play an important role in the treatment of myasthenia gravis.Having a good knowledge of the treatment of refractory myasthenia gravis lay a foundation for improving the clinical manifestations. Key words: Refractory myasthenia gravis; Monoclonal antibody; Immune inhibitors; Surgery
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
